Stockreport

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Initiate Phase II MPox Trial in DRC [TheStreet.com]

NanoViricides, Inc.  (NNVC) 
NASDAQ:AMEX Investor Relations: nanoviricides.com/investorinfo.html
PDF its antiviral candidate NV-387 for the treatment of MPox is expected to begin soon in the Democratic Republic of Congo, with site preparation and staff training schedule [Read more]